Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Obducat receives order for an EITRE® 3 NIL-system from KAUST in Saudi Arabia

OBDUCAT AB (publ) subsidiary Obducat Technologies AB, a leading supplier of lithography solutions based on nanoimprint lithography (NIL), has received an order from KAUST, King Abdullah University of Science and Technology, in Saudi Arabia for the supply of a EITRE 3 NIL-system. The order value amounts to approx. 1.3 million SEK. The EITRE 3 system will be installed at KAUST Nanofabrication Core Lab which supports research in the fields of microelectronics, electronic materials, nanotechnology, MEMS, biomedical and optical devices requiring a low-density particle environment. The

Cerrection - AcouSort: Interim Report 2021-01-01 – 2021-03-31

Correction refers to an updated version of PDF, where a table previously was missing.First quarter (2021-01-01 – 2021-03-31) Income amounted to TSEK 2 802 (2 553). Result before tax TSEK -1 685 (-1 022). Result per share* was SEK -0,15 (-0,10) Equity/assets ratio** amounted to 73 % (78%) 31 March 2021. CEO Comments The first quarter of the year got off to a good start with two new deals in January. Our Japanese distributor Physio-Tech, which since last autumn has worked intensively to introduce our systems AcouTrap and AcouWash on the Japanese market, bought an AcouTrap

PPG Industries, Inc. supplements the tender offer document dated January 14, 2021 relating to the voluntary recommended public cash tender offer for all the shares in Tikkurila Oyj

TIKKURILA OYJTender Offer May 27, 2021 at 9.05 a.m. EEST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. PPG Industries, Inc. (“PPG” or the “Offeror”), a corporation incorporated under the laws of Pennsylvania, and Tikkurila Oyj (“Tikkurila” or the “Company”) have on December 18, 2020 entered into a combination agreement (the “Combination Agreement”), which was amended

Banning the sale of fossil-fuel cars would benefit the climate when they are replaced by electric cars

[Exhaust emissions are emissions within Swedens borders which need to reach zero by 2045 to fully contribute to Swedens climate policy goals Emissions from the production of cars and fuels encompass the manufacture of cars and batteries as well as fuel production including the production of electricity for electric cars The striped fields show the possibilities for emission reductions in the manufacture of batteries vehicles and fuels The diagram assumes a Swedish ban on new sales of petrol and diesel cars in 2030 as well as an increasing usage of biofuels in accordance with the revised

Frill Holding recruits key personnel for continued rapid expansion

STOCKHOLM, May 27, 2021 08:00 CET Nasdaq First North-listed Frill Holding AB (publ) recruits key people within the group, to strengthen the organization during the rapid expansion that the company is implementing. Camilla Lönn will be employed as CFO as of September 1, 2021 and Fredrik Kling has recently been hired as Deputy CEO.“The company is in an exciting and important phase with rapid growth, and we see that there are good conditions for continued expansion. Here, Camilla Lönn and Fredrik Kling will be important personnel to ensure that we create maximum value. The recruitments will

AstraZeneca prices a EUR800m bond offering

27 May 2021 07:00 BST AstraZeneca prices a €800m bond offering   AstraZeneca PLC ("AstraZeneca") announces that, on 26 May 2021, it successfully priced €800m ($1bn equivalent) of fixed rate notes with a coupon of 0.375%, maturing on 3 June 2029 (the "Notes"). The Notes will be subject to special mandatory redemption if the acquisition of Alexion Pharmaceuticals, Inc. ("Alexion") (the "Alexion Acquisition") is not consummated on or before 12 March 2022 or, if prior to such date, AstraZeneca notifies the trustee that AstraZeneca will not pursue the consummation of the Alexion

Q2 2021 - A QUARTER DOMINATED BY THE ONGOING PANDEMIC

FEBRUARY 2021–APRIL 2021 · Revenue: MSEK 1,932 (5,264) · Income before tax (EBT): MSEK -2,361 (-3,722) · Income before tax and items affecting comparability: MSEK -2,361 (-3,714) · Net income for the period: MSEK -2,433 (-3,470) · Earnings per common share: SEK -0.35 (-9.15) SIGNIFICANT EVENTS DURING THE QUARTER · The Board of SAS appointed Anko van der Werff as President and CEO. The Board concurrently appointed Karl Sandlund, Chief Commercial Officer at SAS, as acting President and CEO. · SAS secured financing for the majority of its aircraft deliveries until

Veidekke ASA: To renovate property in Stockholm

Veidekke’s subsidiary Arcona has been commissioned to renovate and extend the property Skjutsgossen 12 on Södermalm in Stockholm.The client is Scius Partners, and the project has a contract value of up to SEK 185 million. The contract is included in the order book for the current quarter. For more information, contact:Mats Nyström, EVP Veidekke Sweden, ph. +46 705 37 12 60  Veidekke press photos  Subscribe to notices from Veidekke 

Serene beauty of Phang Nga – A guide to your day trip

  Phang Nga on the Andaman Coast just north of Phuket is an excellent vacation spot for beach-lovers and honeymoonners. It is family-friendly and has numerous beaches that are ideal for quiet holidays and peaceful relaxation. If you are looking for an active holiday, Phang Nga offers a great deal of various activities such as surfing, diving or exploring the beautiful nature. According to Thailand reopening roadmap plan, from 1 July, 2021 Phuket is set to be the first destination to lift quarantine requirements for vaccinated foreign tourists under the ‘Phuket Sandbox’

Prostatype Genomics presents Interim Report for the period 1 January to 31 March 2021

Prostatype Genomics presents Quarterly report for the first quarter of 2021. The Report is available on the Company's home page.Quarter 1 (1 March – 31 March 2020) summarized · Net sales amounted to 812 TSEK. · Net revenue amounted to 5 TSEK. · EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -3 417 TSEK. · Cash flow from current operations in the quarter amounted -4 514 TSEK. · Total cash flow for the period amounted to -5 342 TSEK. · Earnings per share amounted to -0,26 SEK. Significant events during the First Quarter · In

InDex Pharmaceuticals presents at Redeye Growth Day 2021

May 27, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2021 on June 2 at 8.50 CET. The presentation will be livestreamed and can be followed at https://www.redeye.se/events/808637/redeye-growth-day-2021.The presentation, which will be held in Swedish, will also be available afterwards on https://www.redeye.se/events/808637/redeye-growth-day-2021, on  the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals), as well as on InDex’s website (www.indexpharma.com). For more

LeoVegas exercises authorisation for share repurchases

The Board of Directors of LeoVegas has decided to exercise the authorisation to repurchase own shares granted to it by the company’s Annual General Meeting on 11 May 2021. LeoVegas intends to repurchase shares for an amount up to EUR 10,000,000. The share repurchases will be conducted on one or more occasions before the Annual General Meeting 2022. The purpose is to optimise the company’s capital structure and create shareholder value by reducing the number of shares outstanding. The repurchased shares may also be used as payment for potential future acquisitions. The share repurchase

NILAR INTERIM REPORT Q1 2021

COMMISSIONED THE FOURTH PRODUCTION LINE. COMPLETED THE REPAIR OF THE VENTILATION SYSTEM IN THE PRODUCTION PLANT. January – March 2021 in summary · Revenue 5.4 (4.6) MSEK. · Production 3.2 MWh. · Delivered energy storages 73 (53), average size per energy storage 19 (15) kWh. · Gross profit -69.6 (-41.6) MSEK. · EBITDA -78.0 (-48.3) MSEK. · Operating income (EBIT) -96.0 (-60.9) MSEK. · Net loss -114.4 (-68.0) MSEK. · Earnings per share -22.53 SEK. Significant events during the first quarter · The repair of the ventilation system in the production facility

Eurocine Vaccines publishes interim report for July 2020 - March 2021

Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes the interim report for July 2020 to March 2021. Below is a summary of the report. The full report is available on the Eurocine Vaccines website and as an attachment.2021-01-01– 2021-03-31 (third quarter) · Result after tax during the period amounted to SEK -4,6 million (SEK -2 million) · Revenues during the period amounted to TSEK 75 ( TSEK 8) · Earnings per share during the period SEK -0.582 (SEK -0.006)* 2020-07-01– 2021-03-31 (9 month period) · Result after tax during the

Q1 2021 - Strategically important orders from three different universities

CONSOLIDATED GROUP JANUARY 1 – MARCH 31, 2021 · Total revenues amounted to 740 (662) kSEK · Operating income amounted to -6 008 (-5 506) kSEK · Profit/Loss after financial items amounted to -1 124 (-5 604)  kSEK · Earnings per share amounted to 0 SEK HIGHLIGHTS DURING THE FIRST QUARTER · Metacon broadened its operations by investing in Water2H2 AB, a company that provides complete solutions for the design and delivery of electrolysers. Metacon invested SEK 6 million in exchange for 20 percent of the shares in Water2H2. Additionally, Metacon received a non-binding

Raytelligence - Interim Report January - March 2021

January 1 -  March 31 2021 ·       Net Sales SEK 0 ·       Operation profit SEK -2 212 647 ·       Profit after financial items SEK -2 212 647 ·       Earnings per share SEK -0,10 ·       Numbers of shares 21 907 369  Significant events during the report period (2021-01-01 - 2021-03-31) ·      Raytelligence is listed on the Stuttgart Stock Exchange, Germany ·      Becomes partner in the PICTA project Autumn Leaves for improved case detection in close care Significant events after the report period ·      New release of EaZense ·      Raytelligence signs

Photocure to Present at Two Upcoming Investor Conferences in June

Press Release – Oslo, Norway, 27 May 2021, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews at two upcoming institutional investor conferences in June.Details for the two presentations are as follows:  · The MicroCap Rodeo 2021 Summer Solstice – Best Ideas from the Buyside: June 1-4, 2021. Photocure will present on Tuesday June 1 at 3:00pm CET / 9:00am ET. Management will be available for virtual 1-1 meetings with investors

Bravida acquires E3K, thereby strengthening its position in Stockholm

Bravida is acquiring E3K and thereby strengthening its range of comprehensive services in Stockholm in the areas of installation, service, automation, electrics, HVAC, heating and plumbing, and property management. E3K currently has sales of around SEK 165 million and 100 employees.E3K was founded in 2005 and today operates in the fields of automation, electrics, ventilation, heating and plumbing. The business specialises in holistic services for installation work, property management, and service and technology provision. Other areas of expertise include taking an overarching approach and

Panoro Energy: Q1 2021 Trading and financial update

Oslo, 27 May 2021 - Panoro Energy ASA (“Panoro” or the “Company” with OSE Ticker: PEN) delivered on a pro-forma basis, record high revenues of USD 77.2 million in this year’s first quarter, with an EBITDA-result of USD 25.3 million, showcasing the scale effects of the Company’s announced acquisitions, which either have been or are in process of being completed. On an IFRS Reporting Basis, Panoro had gross revenues of USD 11.8 million, EBITDA of USD 5.3 million and EBIT of USD 3.2 million in this year’s first quarter. Panoro today also notes a target 2021 exit rate production of

Hunter Group ASA - First quarter results 2021

Oslo, 27 May 2021   Financial highlights Total revenues of USD 12.49m - Spot pool revenues of USD 3.13m - Time charter revenues of USD 9.28m Total operating expenses of USD 7.38m - Vessel opex incl insurance of USD 2.60m - Voyage exp and commissions of USD 0.33m - G&A expenses of 0.43m   - USD 0.37m administrative expenses   - USD 0.03m legal expenses   - USD 0.03m non cash expenses EBITDA of USD 9.12m Net profit of USD 2.59m   Average daily earnings of USD 29,650 - Avg daily spot earnings of USD 21,020 - Avg daily time charter earnings

Nanoform Interim Report January – March (Q1) 2021

Company Announcement Nanoform Finland Plc May 27, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Interim Report January – March (Q1) 2021 Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP[®] launched, EUR 40 million successfully raised and commercial teams in the US

Herantis Pharma Hosts Virtual R&D Investor Day on June 8, 2021

Herantis Pharma Hosts Virtual R&D Investor Day on June 8, 2021 Herantis Pharma Plc, Company release,  27 May 2021 at 8:00 AM EEST Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, will host its virtual R&D Investor Day on Tuesday, June 8, 2021 from 14:00 – 16:00 EEST / 13:00 – 15:00 CEST. Herantis’ business executives and scientific leadership will provide updates on the company’s progress in advancing its R&D pipeline, specifically the Company’s disease modifying assets Cerebral Dopamine Neurotrophic

Willys leases 1,750 sq m on Första Långgatan in Gothenburg

In spring 2022, Willys Hemma will open a new store with a floor space of 1,750 square meters in Wallenstam’s premises at Första Långgatan 16 in Gothenburg. This will be a purposeful store establishment with Willy’s concept and a lease which has been entered into for ten years. It will be a store with a focus on a broad and varied assortment, a lot of perishable produce and a large proportion of ecological and eco-labeled products.“We see great potential for Willys Hemma store on Första Långgatan, which will have a location with exciting future prospects and which is undergoing great

There are no items matching the current filter
There are no more items matching the current filter
Back to top